Key Highlights
- Shares of Can-Fite BioPharma (CANF) climbed by as much as 65% on Wednesday following the disclosure of Phase 2a clinical trial data for Namodenoson in patients with advanced pancreatic cancer.
- The trial successfully achieved its primary safety objective among 20 participants who had previously failed standard treatment options.
- Among third-line treatment patients, the median overall survival surpassed five months, with 37.5% of patients living seven months or beyond.
- A notable second-line patient survived more than 18 months after initiating Namodenoson therapy — marking the longest survival duration recorded in the trial.
- The company intends to move forward with a Phase 2b trial combining Namodenoson with chemotherapy treatment.
Shares of Can-Fite BioPharma (CANF) experienced a dramatic surge of up to 65% during Wednesday’s trading session after the biotechnology firm unveiled findings from its Phase 2a clinical evaluation of Namodenoson in patients suffering from advanced pancreatic ductal adenocarcinoma (PDAC). Trading activity showed the stock hovering around $2.97 per share in the wake of the announcement.
The open-label clinical investigation enrolled a total of 20 participants — each having previously experienced disease progression despite receiving standard therapeutic interventions. Among these patients, 14 were administered Namodenoson as third-line treatment, five received it as second-line therapy, and one patient was treated at the fourth-line stage.
The clinical trial successfully achieved its primary safety objective. Namodenoson demonstrated good tolerability among participants, with adverse event profiles aligning with observations from previous clinical investigations.
An updated survival assessment focusing on eight evaluable third-line patients who lived at least two months following treatment initiation revealed that median overall survival exceeded the five-month threshold. This represents a significant milestone for a condition where therapeutic alternatives become severely limited at advanced stages.
Among this patient cohort, 62.5% achieved survival of five months or greater. Additionally, 37.5% reached survival durations of seven months or more. At the time of data analysis, two patients remained alive.
The second-line treatment group yielded particularly striking findings. One individual continued to survive beyond 18 months after commencing Namodenoson treatment — representing the most extended survival duration observed across the entire study population.
Principal Investigator’s Perspective
Prof. Salomon Stemmer, who serves as the lead researcher for the Phase 2a investigation at the Davidoff Institute of Oncology within Rabin Medical Center in Israel, characterized the Namodenoson monotherapy outcomes as “impressive.”
He emphasized the encouraging safety characteristics and the extended survival observed within a patient subset as indicators of meaningful biological activity warranting additional investigation. Prof. Stemmer indicated that the rational progression involves assessing Namodenoson when combined with chemotherapy agents.
Preclinical research has demonstrated that the drug can augment the anti-tumor effectiveness of chemotherapeutic compounds in pancreatic cancer experimental models, establishing the scientific rationale for this subsequent phase.
Future Development Strategy
Can-Fite is preparing to advance Namodenoson into a Phase 2b combination trial with chemotherapy, leveraging both the Phase 2a clinical findings and supporting preclinical evidence.
The biotechnology company currently maintains a market capitalization of approximately $5.87 million and holds a GF Score of 55 out of 100, suggesting moderate growth prospects while registering low ratings for profitability (1/10) and financial strength (4/10).
Insider transaction records show no buying or selling activity in CANF shares throughout the preceding 12-month period.
The price-to-sales ratio presently registers at 5.32. For a clinical-stage biotechnology enterprise of this scale, the clinical trial findings are the primary catalyst behind market movement — rather than underlying financial metrics.
